Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted treatment for HIV-associated Hodgkin Lymphoma
NCT01468740Phase 2Unknown
- Sponsor
- Harlachinger Krebshilfe
- Start
- Mar 2004
- Primary completion
- Feb 2012
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide in Hodgkin lymphoma (HL), sponsored by Harlachinger Krebshilfe. Status: unknown.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01468740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468740.